ELSEVIER

Journal of Controlled Release 57 (1999) 315–316

journal of controlled release

Author Index Volume 57 (1999)

Abd El-Ghaffar, M.A., see Helaly, F.M. (57) 1
Abu Fara, D., see Al-Musa, S. (57) 223
Ahmed, A.A., see Helaly, F.M. (57) 1
Akamatsu, K., see Yura, H. (57) 87
Al-Musa, S., Abu Fara, D. and Badwan, A.A., Evaluation of parameters involved in preparation and release of drug loaded in crosslinked matrices of alginate (57) 223
Anderson, D., see Julyan, P.J. (57) 281
Anderson, J.M. and Langone, J.J., Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems (57) 107
Anseth, K.S., see Lu, S. (57) 291
Anwar, H., see Owusu-Ababio, G. (57) 151
Atterholt, C.A., Delwiche, M.J., Rice, R.E. and Krochta, J.M., Controlled release of insect sex pheromones from paraffin wax and emulsions (57) 233

Badwan, A.A., see Al-Musa, S. (57) 223
Benita, S., see Klang, S.H. (57) 19
Bodmeier, R., see Schmidt, C. (57) 115
Boivin, C.M., see Julyan, P.J. (57) 281

Cardinal, J.R., see Thombre, A.G. (57) 55
Cardinal, J.R., see Thombre, A.G. (57) 65
Christodoulou, C., see Julyan, P.J. (57) 281

Daryani, S., see Julyan, P.J. (57) 281
David, M., see Julyan, P.J. (57) 281
Davis, S.S., see Govender, T. (57) 171
Dellacherie, E., see Görner, T. (57) 259
Delwiche, M.J., see Atterholt, C.A. (57) 233
DeNoto, A.R., see Thombre, A.G. (57) 55
DeNoto, A.R., see Thombre, A.G. (57) 65
Doran, J., see Julyan, P.J. (57) 281
Du, B., see Zhuo, R.X. (57) 249
Dunmire, E.N., Plenys, A.M. and Katz, D.F., Spectrophotometric analysis of molecular transport in gels (57) 127

Ehtezazi, T., Washington, C. and Melia, C.D., Determination of the internal morphology of poly (D,L-lactide) microspheres using stereological methods (57) 301
Eichler, H.G., see Luftensteiner, C.P. (57) 35
El-Mir, M.Y., see Macias, R.I.R. (57) 161
Eshraghi, J., see Yang, L. (57) 215

Fassihi, R., see Yang, L. (57) 215
Ferry, D.R., see Julyan, P.J. (57) 281
Ford, J.L., see Velasco, M.V. (57) 75
Frucht-Pery, J., see Klang, S.H. (57) 19

Gadras, C., Santaella, C. and Vierling, P., Improved stability of highly fluorinated phospholipid-based vesicles in the presence of bile salts (57) 29
Garcia, M.J., see Macias, R.I.R. (57) 161
Garnett, M.C., see Govender, T. (57) 171
Gibbes, D.C., see Thombre, A.G. (57) 65
Görner, T., Gref, R., Michenot, D., Sommer, F., Tran, M.N. and Dellacherie, E., Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix (57) 259
Govender, T., Stolnik, S., Garnett, M.C., Illum, L. and Davis, S.S., PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug (57) 171
Gref, R., see Görner, T. (57) 259

Hamashima, T., see Yura, H. (57) 87
Hashida, M., see Yura, H. (57) 87
Hatano, H., see Ishibashi, T. (57) 45
Helaly, F.M., Ahmed, A.A. and Abd El-Ghaffar, M.A., Natural rubber base matrix containing *Calendula officinalis* plant as a source of molluscicdal saponin (57) 1
Herbig, S.M., see Thombre, A.G. (57) 55
Hesslewood, S., see Julyan, P.J. (57) 281

Illum, L., see Govender, T. (57) 171
Ishibashi, T., Hatano, H., Kobayashi, M., Mizobe, M. and Yoshino, H., In vivo drug release behavior in dogs from a new colon-targeted delivery system (57) 45

Julyan, P.J., Seymour, L.W., Ferry, D.R., Daryani, S., Boivin, C.M., Doran, J., David, M., Anderson, D., Christodoulou, C., Young, A.M., Hesslewood, S. and Kerr, D.J., Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine (57) 281

Katz, D.F., see Dunmire, E.N. (57) 127
Kerr, D.J., see Julyan, P.J. (57) 281
Kim, C.-j., see Konar, N. (57) 141

PII: S0168-3659(99)00002-4

Klang, S.H., Siganos, C.S., Benita, S. and Frucht-Pery, J., Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn (57) 19
Kobayashi, M., see Ishibashi, T. (57) 45
Koerten, H.K., see Marttin, E. (57) 205
Konar, N. and Kim, C.-j., Drug release from drug-polyanion complex tablets: poly(acrylamido-2-methyl-1-propanesulfonate sodium -co- methyl methacrylate) (57) 141
Krochta, J.M., see Atterholt, C.A. (57) 233
Kwon, G.S., see Wang, D. (57) 9

Langone, J.J., see Anderson, J.M. (57) 107
Lee, K.H., see Oh, J.E. (57) 269
Lu, S. and Anseth, K.S., Photopolymerization of multilaminated poly(HEMA) hydrogels for controlled release (57) 291
Lu, Z.R., see Zhuo, R.X. (57) 249
Luftensteiner, C.P., Schwendenwein, I., Paul, B., Eichler, H.G. and Viernstein, H., Evaluation of mitoxantrone-loaded albumin microspheres following intraperitoneal administration to rats (57) 35

Macias, R.I.R., El-Mir, M.Y., Monte, M.J., Serrano, M.A., Garcia, M.J. and Marin, J.J.G., Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2) (57) 161
Majid Khan, G. and Zhu, J.-B., Studies on drug release kinetics from ibuprofen–carbomer hydrophilic matrix tablets: influence of co-excipients on release rate of the drug (57) 197
Marin, J.J.G., see Macias, R.I.R. (57) 161
Marttin, E., Verhoef, J.C., Spies, F., van der Meulen, J., Nagelkerke, J.F., Koerten, H.K. and Merkus, F.W.H.M., The effect of methylated β-cyclodextrins on the tight junctions of the rat nasal respiratory epithelium. Electron microscopic and confocal laser scanning microscopic visualization studies (57) 205
Melia, C.D., see Ehtezazi, T. (57) 301
Merkus, F.W.H.M., see Marttin, E. (57) 205
Michenot, D., see Görner, T. (57) 259
Mizobe, M., see Ishibashi, T. (57) 45
Monte, M.J., see Macias, R.I.R. (57) 161

Nagelkerke, J.F., see Marttin, E. (57) 205
Nam, Y.S., see Oh, J.E. (57) 269
Nishikawa, M., see Yura, H. (57) 87

Oh, J.E., Nam, Y.S., Lee, K.H. and Park, T.G., Conjugation of drug to poly(D,L-lactic-co-glycolic acid) for controlled release from biodegradable microspheres (57) 269
Owusu-Ababio, G., Rogers, J. and Anwar, H., Effectiveness of ciprofloxacin microspheres in eradicating bacterial biofilm (57) 151

Park, T.G., see Oh, J.E. (57) 269
Paul, B., see Luftensteiner, C.P. (57) 35
Plenys, A.M., see Dunmire, E.N. (57) 127

Rajabi-Siahboomi, A.R., see Velasco, M.V. (57) 75
Rice, R.E., see Atterholt, C.A. (57) 233
Robinson, D.R., see Wang, D. (57) 9
Rogers, J., see Owusu-Ababio, G. (57) 151
Rowe, P., see Velasco, M.V. (57) 75

Samuel, J., see Wang, D. (57) 9
Santaella, C., see Gadras, C. (57) 29
Schacht, E., see Soyez, H. (57) 187
Schmidt, C. and Bodmeier, R., Incorporation of polymeric nanoparticles into solid dosage forms (57) 115
Schwendenwein, I., see Luftensteiner, C.P. (57) 35
Serrano, M.A., see Macias, R.I.R. (57) 161
Seymour, L.W., see Julyan, P.J. (57) 281
Seymour, L.W., see Soyez, H. (57) 187
Siganos, C.S., see Klang, S.H. (57) 19
Smith, K.L., see Thombre, A.G. (57) 55
Sommer, F., see Görner, T. (57) 259
Soyez, H., Seymour, L.W. and Schacht, E., Macromolecular derivatives of *N,N*-di-(2-chloroethyl)-4-phenylene diamine mustard. 2. In vitro cytotoxicity and in vivo anticancer efficacy (57) 187
Spies, F., see Marttin, E. (57) 205
Stolnik, S., see Govender, T. (57) 171

Takakura, Y., see Yura, H. (57) 87
Thombre, A.G., Cardinal, J.R., DeNoto, A.R. and Gibbes, D.C., Asymmetric membrane capsules for osmotic drug delivery II. In vitro and in vivo drug release performance (57) 65
Thombre, A.G., Cardinal, J.R., DeNoto, A.R., Herbig, S.M. and Smith, K.L., Asymmetric membrane capsules for osmotic drug delivery. I. Development of a manufacturing process (57) 55
Tran, M.N., see Görner, T. (57) 259

van der Meulen, J., see Marttin, E. (57) 205
Velasco, M.V., Ford, J.L., Rowe, P. and Rajabi-Siahboomi, A.R., Influence of drug:hydroxypropylmethylcellulose ratio, drug and polymer particle size and compression force on the release of diclofenac sodium from HPMC tablets (57) 75
Verhoef, J.C., see Marttin, E. (57) 205
Vierling, P., see Gadras, C. (57) 29
Viernstein, H., see Luftensteiner, C.P. (57) 35

Wang, D., Robinson, D.R., Kwon, G.S. and Samuel, J., Encapsulation of plasmid DNA in biodegradable poly(D,L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery (57) 9
Washington, C., see Ehtezazi, T. (57) 301

Yang, L., Eshraghi, J. and Fassihi, R., A new intragastric delivery system for the treatment of *Helicobacter pylori* associated gastric ulcer: *in vitro* evaluation (57) 215
Yoshimura, N., see Yura, H. (57) 87
Yoshino, H., see Ishibashi, T. (57) 45
Young, A.M., see Julyan, P.J. (57) 281
Yura, H., Yoshimura, N., Hamashima, T., Akamatsu, K., Nishikawa, M., Takakura, Y. and Hashida, M., Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506–dextran conjugate (57) 87

Zhu, J.-B., see Majid Khan, G. (57) 197
Zhuo, R.X., Du, B. and Lu, Z.R., In vitro release of 5-fluorouracil with cyclic core dendritic polymer (57) 249

ELSEVIER

Journal of Controlled Release 57 (1999) 317–318

journal of controlled release

Subject Index Volume 57 (1999)

Albumin microspheres, (57) 35
Alkali burn, (57) 19
Anticancer efficacy, (57) 187
Antigen delivery, (57) 9
Asialoglycoprotein receptor, (57) 281
Asymmetric membrane capsule(s), (57) 55, (57) 65
Bacterial biofilm, (57) 151
Beagle dog, (57) 45
Bile acid, (57) 161
Biocompatibility, (57) 107
Biodistribution, (57) 87
Calendula officinalis, (57) 1
Cancer, (57) 161
Carbopol® 934P and 971P, (57) 197
Chemotherapy, (57) 161
Ciprofloxacin, (57) 151
Co-excipients, (57) 197
Colloidal carriers, (57) 115
Colon-targeted delivery, (57) 45
Complex, (57) 141
Compression force, (57) 75
Confocal laser scanning microscopy, (57) 205
Conjugation, (57) 269
Controlled drug release, (57) 215
Controlled release, (57) 107, (57) 141, (57) 223, (57) 233, (57) 259
Cyclodextrins, (57) 205
Cytotoxicity, (57) 187
DNA delivery, (57) 9
Degradation-controlled, (57) 269
Dendrimer, (57) 249
Detergent, (57) 29
Dextran, (57) 87
Diclofenac sodium, (57) 75
Diffusion- and swelling-controlled release, (57) 197
Diffusion-controlled release, (57) 291
Diffusion, (57) 127
Dissociation, (57) 141
Doxorubicin, (57) 281
Drug delivery mechanism, (57) 65
Drug incorporation, (57) 171
Drug release, (57) 223
Drug:HPMC ratio, (57) 75
Electron microscopy, (57) 205
Encapsulation, (57) 259
Erosion, (57) 141
Eudragit®E, (57) 45
FK506–dextran conjugate, (57) 87
Film crosslinking, (57) 223
Flocculation, (57) 115
Fluorinated liposomes, (57) 29
Fluorinated phospholipids, (57) 29
5-Fluorouracil, (57) 249
Food effect, (57) 45
Galactose, (57) 281
Gastric emptying, (57) 45
Gels, (57) 127
HPMA copolymers, (57) 281
HPMC, (57) 75
HPMC®-AS, (57) 45
Hard gelatin capsule, (57) 45
Ibuprofen, (57) 197
Imaging, (57) 281
Immunotoxicity, (57) 107
In vivo, (57) 35
In vitro and in vivo release, (57) 65
In vitro release profile, (57) 127
In vitro release, (57) 171
Intragastric drug delivery, (57) 215
Intraperitoneal chemotherapy, (57) 35
Kidney, (57) 161
Lidocaine, (57) 259
Liver, (57) 161
Manual and semiautomatic manufacture, (57) 55
Mating disruption, (57) 233
Matrix tablets, (57) 197
Metal, (57) 161
Membranes, (57) 29
Michael addition, (57) 249
Microsphere(s), (57) 9, (57) 269, (57) 301
Mitoxantrone, (57) 35
Modeling, (57) 291
Multivariate confidence ellipses, (57) 127
Nanoparticles, (57) 115, (57) 171, (57) 259
Nanoprecipitation, (57) 171
Nasal drug delivery, (57) 205

PII: S0168-3659(99)00003-6

Natural rubber, (57) 1
N,*N*-Di-(2-chloroethyl)-4-phenylene diamine mustard, (57) 187
Nonuniform initial drug loading, (57) 291
Oral dosage forms, (57) 115
Oriental fruit moth, (57) 233
Osmotic delivery, (57) 65
Paraffin, (57) 233
Particle size, (57) 75
Permeability, (57) 29
Pharmacokinetics, (57) 87, (57) 161
Phase inversion, (57) 55
Pheromone, (57) 233
Photopolymerization, (57) 291
Piroxicam, (57) 19
Platinum, (57) 161
PLGA, (57) 171, (57) 269
Poly (D,D-lactide), (57) 301
Poly(D,L-lactic acid), (57) 259
Poly(D,L-lactic-co-glycolic acid), (57) 9
Poly(L-lactic acid), (57) 151
Poly[N^5-(2-hydroxyethyl)-L-glutamine] prodrug, (57) 187
Polyelectrolyte, (57) 141
Polymer dispersions, (57) 115
Polymer matrices, (57) 223
Pore size distribution, (57) 301
Porosity, (57) 301
Positively charged emulsion, (57) 19
Prodrug, (57) 87
Re-epithelization, (57) 19
Redispersibility, (57) 115
Release, (57) 249
Robotic process, (57) 55
Saponin, (57) 1
Sodium alginate, (57) 223
Sodium taurodihydrofusidate, (57) 205
Specific surface area, (57) 301
Stereology, (57) 301
Sulfonate, (57) 141
Sustained release, (57) 35, (57) 151
Tacrolimus (FK506), (57) 87
1,4,7,10-Tetraazacyclododecane, (57) 249
Tetracycline and metronidazole, (57) 215
Tight junctions, (57) 205
Treatment of *Helicobacter pylori*, (57) 215
Triple therapy, (57) 215
Tumor, (57) 161
Tumour-associated enzymes, (57) 187
UV spectrophotometry, (57) 127
Ulceration process, (57) 19
Vaccines, (57) 9
Vesicles, (57) 29
Vulcanizate, (57) 1
Zero-order release, (57) 269